Real-world check: does ilaris work safely for rare fever diseases?

NCT ID NCT06838143

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study watches children and adults who are already taking or about to start Ilaris for hereditary periodic fever syndromes or systemic juvenile idiopathic arthritis. Researchers will track side effects and how well the drug controls symptoms over 16 weeks. No new medicine is tested; the goal is to see how Ilaris performs in everyday medical practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLCHICINE RESISTANCE FAMILIAL MEDITERRANEAN FEVER (CRFMF) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cryopyrin-associated periodic syndrome familial Mediterranean fever hereditary periodic fever syndrome hyperimmunoglobulinemia D with periodic fever juvenile idiopathic arthritis mevalonate kinase deficiency systemic-onset juvenile idiopathic arthritis TNF receptor 1-associated periodic fever syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLCHICINE RESISTANCE FAMILIAL MEDITERRANEAN FEVER (CRFMF) CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS) HEREDITARY PERIODIC FEVER SYNDROMES HYPER-IGD SYNDROME / MEVALONATE KINASE DEFICIENCY (HIDS/MKD) SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA) TNF RECEPTOR ASSOCIATED PERIODIC SYNDROME (TRAPS)

Real-world check: does ilaris work safely for rare fever diseases?

Summary

Get notified about this study

Conditions

As listed by the trial registrant

Contacts and locations

Locations

More trials for these conditions